Furthermore, preclinical evidence suggests a therapeutic implication of immunomodulatory imide drugs (IMiDs) and targeted therapy in the context of altered IKZF1 in a variety of hematological neoplasms. This evidence concerns the gene IKZF1 and hematopoietic and lymphoid system neoplasm.